Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab for Preventive Treatment of Chronic Migraine (Japan Phase III)
jRCT2031210093Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of eptinezumab in chronic migraine (3 arms), sponsored by Lundbeck. Primary endpoint: Change from baseline in monthly migraine days (Weeks 1–12). Started Jul 2021; status: completed.
02
Drugs
eptinezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on jRCT2031210093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210093.